医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TOKYO

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai located in London, changed its corporate name to Chugai Pharma Europe Ltd. (CPE) effective from November 27.

The name change is part of Chugai’s reorganization to accelerate its overseas operation as announced on June 25. In the reorganization, Chugai integrated and gathered its development and commercial entities in Europe that had been separated subsidiaries into one single company. Now under the name of Chugai Pharma Europe, the company will function as Chugai’s European hub to lead clinical development, regulatory affairs, medical affairs, import, sales and marketing of pharmaceutical products in Europe.

“We have now formed a new European Headquarters organization that will enhance our abilities to strongly advance our activities in Europe. Our scope includes conducting clinical trials for investigational drugs from Chugai as well as marketing collaboration with Roche for a rheumatoid arthritis agent RoActemra^® and an upcoming new drug.” said John Halls, Managing Director of CPE. “I’m convinced that we will contribute to Chugai’s aspiration to become a global company.”

With further streamlined operations, CPE will pursue its effort to add exceptional value through innovative medical products and services for the benefit of the medical community and human health around the world.

About Chugai Pharmaceutical Co., Ltd. (Chugai)

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).

Additional information is available on the internet at http://www.chugai-pharm.co.jp/english.

About Chugai Pharma Europe Ltd. (CPE)

Chugai Pharma Europe based in London, is the headquarters of all Chugai’s clinical development, regulatory affairs, medical affairs, import, sales and marketing of pharmaceutical products in Europe and coordinates the European marketing operations through subsidiaries located in the UK, France, and Germany. Products which are currently marketed in those countries include “RoActemra^® (tocilizumab)”, a humanized anti-human IL-6 receptor monoclonal antibody, “Granocyte^® (lenograstim)”, a G-CSF preparation, “Antepsin^® (sucralfate)”, an antiulcer agent (marketed in the UK and Ireland), “Akynzeo^® (netupitant-palonosetron)”, and “Aloxi^® (palonosetron)” antiemetic agents (marketed in the UK). Furthermore, CPE is conducting the clinical development of SA237, an anti-IL-6 receptor humanized monoclonal antibody for the treatment of neuromyelitis optica, and CIM331, an anti-IL-31 receptor humanized monoclonal antibody for the treatment of atopic dermatitis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151130005365/en/